Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)

Subjects

Subjects :

0301 basic medicine
Oncology
Sorafenib
medicine.medical_specialty
Second line treatment
Elevated alpha-fetoprotein
business.industry
First line
Hematology
medicine.disease
Ramucirumab
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
Hepatocellular carcinoma
medicine
Patient-reported outcome
In patient
business
medicine.drug

Details

ISSN :

09237534

Volume :

29

Database :

OpenAIRE

Journal :

Annals of Oncology

Accession number :

edsair.doi...........c99e41229054e7a64a28e64ca6a8da41

Full Text :

https://doi.org/10.1093/annonc/mdy282.006